Cross-Attribute Matrix Factorization Model with Shared User Embedding

Over the past few years, deep learning has firmly established its prowess across various domains, including computer vision, speech recognition, and natural language processing. Motivated by its outstanding success, researchers have been directing their efforts towards applying deep learning techniques to recommender systems. Neural collaborative filtering (NCF) and Neural Matrix Factorization (NeuMF) refreshes the traditional inner product in matrix factorization with a neural architecture capable of learning complex and data-driven functions. While these models effectively capture user-item interactions, they overlook the specific attributes of both users and items. This can lead to robustness issues, especially for items and users that belong to the "long tail". Such challenges are commonly recognized in recommender systems as a part of the cold-start problem. A direct and intuitive approach to address this issue is by leveraging the features and attributes of the items and users themselves. In this paper, we introduce a refined NeuMF model that considers not only the interaction between users and items, but also acrossing associated attributes. Moreover, our proposed architecture features a shared user embedding, seamlessly integrating with user embeddings to imporve the robustness and effectively address the cold-start problem. Rigorous experiments on both the Movielens and Pinterest datasets demonstrate the superiority of our Cross-Attribute Matrix Factorization model, particularly in scenarios characterized by higher dataset sparsity

6-Hydroximino-4-Aza-A-Homo-Cholest-3-One and Related Analogue as A Potent Inducer of Apoptosis in Cancer Cells

Here we report that 6-hydroximino-4-aza-A-homo-cholest-3-one and 6-hydroxyl-4-aza-A-homo-cholest-3-one, new steroidal lactams were synthesized recently, displayed antiproliferative activity against some cancer cells through inducing cancer cell apoptosis by activation of the intrinsic pathway. The apoptotic function of the compounds was demonstrated by release of cytochrome C, activation of caspase 3 and annexin V labeling. Furthermore, the compound was able to inhibit tumor growth in an athymic mouse model

Determining the Biodegradability of Leachate Through XAD-8 Adsorption

AbstractKnowledge of biodegradability of leachate during municipal solid waste disposal is important for this process. The traditional indicator BOD5/COD can characterize the leachate stability, but the experiment of BOD5 lasts long time and success or failure is often affected by various factors, such as the seed, solution times, dilution multiple, and high levels of nitrate and nitrite. The present study was built up an innovative method with short time to determine the biodegradability of leachate by using XAD-8 resin. The leachate was sampled from the aerobic, semi-aerobic, and anaerobic degradations of municipal solid waste. The degradability of leachate could be determined using the formula given by 1-2.084CODXAD/COD. When the CODXAD/COD ratio is greater than 0.432, the leachate is expected to be stable

ViTASD: Robust Vision Transformer Baselines for Autism Spectrum Disorder Facial Diagnosis

Autism spectrum disorder (ASD) is a lifelong neurodevelopmental disorder with very high prevalence around the world. Research progress in the field of ASD facial analysis in pediatric patients has been hindered due to a lack of well-established baselines. In this paper, we propose the use of the Vision Transformer (ViT) for the computational analysis of pediatric ASD. The presented model, known as ViTASD, distills knowledge from large facial expression datasets and offers model structure transferability. Specifically, ViTASD employs a vanilla ViT to extract features from patients' face images and adopts a lightweight decoder with a Gaussian Process layer to enhance the robustness for ASD analysis. Extensive experiments conducted on standard ASD facial analysis benchmarks show that our method outperforms all of the representative approaches in ASD facial analysis, while the ViTASD-L achieves a new state-of-the-art. Our code and pretrained models are available at https://github.com/IrohXu/ViTASD.Comment: 5 pages, 3 figures, Accepted by the ICASSP 202

Synthesis and Evaluation of Some 17-Acetamidoandrostane and N,N-Dimethyl-7-deoxycholic Amide Derivatives as Cytotoxic Agents: Structure/Activity Studies

Using pregnenolone and 7-deoxycholic acid as starting materials, some 17-acetamidoandrostane and N,N-dimethyl-7-deoxycholic amide derivatives were synthesized. The cytotoxicity of the synthesized compounds was tested in vitro against two tumor cell lines: SGC 7901 (human gastric carcinoma) and Bel 7404 (human liver carcinoma). The result showed that the blockage of the interaction of the amide group with outside groups might cause a decrease of the cytotoxicity, and an O-benzyloximino group at the 3-position of N,N-dimethyl-7-deoxycholic amide could enhance the cytotoxic activity of the compound. The information obtained from the studies provides the structure-activity relationship for these compounds and may be useful for the design of novel chemotherapeutic drugs

Synthesis and Evaluation of Some 17-Acetamidoandrostane and N,N-Dimethyl-7-deoxycholic Amide Derivatives as Cytotoxic Agents: Structure/Activity Studies

Using pregnenolone and 7-deoxycholic acid as starting materials, some 17-acetamidoandrostane and N,N-dimethyl-7-deoxycholic amide derivatives were synthesized. The cytotoxicity of the synthesized compounds was tested in vitro against two tumor cell lines: SGC 7901 (human gastric carcinoma) and Bel 7404 (human liver carcinoma). The result showed that the blockage of the interaction of the amide group with outside groups might cause a decrease of the cytotoxicity, and an O-benzyloximino group at the 3-position of N,N-dimethyl-7-deoxycholic amide could enhance the cytotoxic activity of the compound. The information obtained from the studies provides the structure-activity relationship for these compounds and may be useful for the design of novel chemotherapeutic drugs